Recent ASND Stock Price | ASND Stock Predictions | |
$148.97 | +19.29% |
$177.70 |
Recent ASND Analyst Ratings Breakdown, Making ASND Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 10 | 10 | 10 | 10 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 3 | 3 | 3 | 3 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.46 | 1.46 | 1.46 | 1.46 |
For the ASND stock predictions from the analysts covering Ascendis Pharma A/S, we have collected all of the individual ASND stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 10 different analysts covering ASND (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since ASND stock predictions may vary widely, another useful metric to consider is the median ASND stock prediction, which represents the price at which half of the analysts
made ASND stock predictions that were higher and half made ASND stock predictions that were lower. This makes for a different take on the ASND stock predictions out there, as compared to average or mean.
And that median across all the individual ASND stock predictions was: $171.5 as of 2024-03-28.
The very highest of the ASND stock predictions for one year price target was $260.0, while the very lowest of the ASND stock predictions in the analyst group was
$116.0 (with a standard deviation of $39.488). Get the latest Zacks research report on ASND — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
AXS Stock Predictions
AU Stock Predictions
MO Stock Predictions
IRET Stock Predictions
FRGI Stock Predictions
TW Stock Predictions
NDLS Stock Predictions
LANC Stock Predictions
ORBC Stock Predictions
|
|
Strong Buy (3.54 out of 4) 64th percentile
(ranked higher than approx. 64% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |